Can Pharmacogenomics Guide Effective Anticancer Therapy in Pancreatic Ductal Adenocarcinoma?

Pharmacogenomics - United Kingdom
doi 10.2217/pgs.12.73
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Non-Coding RNAs in Pancreatic Ductal Adenocarcinoma

Frontiers in Oncology
Cancer ResearchOncology
2020English

Pancreatic Ductal Adenocarcinoma With Cystic Features

HPB
HepatologyGastroenterology
2016English

Tumor-Stroma Interactions in Pancreatic Ductal Adenocarcinoma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2007English

Tumoral EHF Predicts the Efficacy of Anti-Pd1 Therapy in Pancreatic Ductal Adenocarcinoma

Journal of Experimental Medicine
MedicineAllergyImmunology
2019English

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)

International Journal of Medical Sciences
Medicine
2020English

Clinical Significance of MUC13 in Pancreatic Ductal Adenocarcinoma

HPB
HepatologyGastroenterology
2018English

Pancreatic Ductal Adenocarcinoma inBRCA2mutation Carriers: Table 1

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2016English

Features of Immunophenotype of Pancreatic Ductal Adenocarcinoma

Zaporozhye Medical Journal
2014English

Desmogleins as Prognostic Biomarkers in Resected Pancreatic Ductal Adenocarcinoma

British Journal of Cancer
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy